# Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis

## TL;DR

Less frequent mammograms for older breast cancer patients are cost-effective and save money without harming survival outcomes.

## Contribution

The study provides cost-effectiveness and budget impact evidence for less frequent mammogram surveillance in older breast cancer patients.

## Key findings

- Less frequent mammograms saved £543.88 per patient over 5 years.
- NHS savings of £185.87 million are projected over 6 years.
- Cost-effectiveness was improved when societal costs were included.

## Abstract

There is limited evidence on the optimal frequency of mammogram surveillance. At 5-year follow-up, the Mammo-50 trial found that, in patients aged 50+ and 3 years post diagnosis, less frequent mammograms were non-inferior to annual mammograms for breast-cancer-specific-survival, recurrence-free interval and overall survival.

A within-trial cost-effectiveness analysis compared annual versus less frequent mammogram surveillance over 5 years from healthcare and societal perspectives. Hospital Episodes Statistics captured hospital-based resource use. Health-related quality of life and other cost data were obtained via questionnaires at surveillance mammograms. A budget impact analysis estimated NHS savings.

Less frequent surveillance led to cost savings of −£543.88 (−£1116; £26) and a small reduction in quality-adjusted life years (QALYs) of −0.02 (−0.095; 0.06) per patient. The incremental net monetary benefit at a £20,000/QALY threshold was £187 (−£1574; £2027). Including societal costs increased savings to £1543 per person (−£2416; −£669), and cost-effectiveness. Projected NHS savings were £185.87 million over 6 years.

Less frequent mammogram surveillance is cost-effective. Uncertainty remains due to variability in costs and quality of life estimates, and missing data in the less frequent arm due to study design. Given the trial’s non-inferiority findings, this strategy is recommended from healthcare and societal perspectives.